获取途径

作者

Yanxin Sun, Zhenzhen Deng, Haifeng Sun, Xiaojuan Wei, Leirong Wang, Shuyun Wang, Aiqin Gao, Yuping Sun, Juan Li

作者单位

Affiliations ¹ School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, China. ² Phase I Clinical Trail Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. ³ Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China. ⁴ Phase I Clinical Research Center, Shandong University Cancer Center, Jinan, Shandong, China. ⁵ Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.

刊名

International journal of cancer

年份

2025

ISSN

1097-0215

关键词

immunochemotherapy immunotherapy timing lung adenocarcinoma overall survival progression‐free survival.

摘要

Immunochemotherapy combinations have been the standard first-line therapy for advanced lung adenocarcinoma without driver mutations, wherein concurrent chemotherapy and immunotherapy are conventionally anchored in the established dosing regimen. A few studies have suggested that the timing of immunotherapy in combinations may have a significant impact on the efficacy. However, this issue has not been addressed in an advanced LUAD cohort. We aimed to investigate the prognostic significance of th...更多

Immunochemotherapy combinations have been the standard first-line therapy for advanced lung adenocarcinoma without driver mutations, wherein concurrent chemotherapy and immunotherapy are conventionally anchored in the established dosing regimen. A few studies have suggested that the timing of immunotherapy in combinations may have a significant impact on the efficacy. However, this issue has not been addressed in an advanced LUAD cohort. We aimed to investigate the prognostic significance of the timing of immunotherapy in first-line immunochemotherapy combinations for patients with advanced LUAD. We retrospectively analyzed 508 patients with advanced LUAD without driver mutations who received immunochemotherapy as initial systemic treatment. The patients were divided into two groups-the induction and non-induction groups-with induction defined as receiving chemotherapy alone before concurrent immunochemotherapy. The bias between different groups was minimized using propensity score matching . We found both the PFS and OS of the patients in the induction group were significantly longer than those in the non-induction group before and after PSM . After adjusting for confounders, induction chemotherapy was still a significant favorable factor for both PFS and OS . In subsequent analyses, we found that both ≥2-cycles induction and 1-cycle induction were superior to non-induction and these differences were still significant after PSM. Our findings highlight the notable benefits of induction chemotherapy for patients with advanced LUAD treated with first-line immunochemotherapy combinations.收起

文献类型

期刊

浏览量

4